Correlation between phosphorylation of PEA-15-Ser104 site and prognosis of epithelial ovarian cancer

doi:10.12092/j.issn.1009-2501.2019.05.007

Abstract

Abstract:

AIM: To detect the expression level of pPEA-15-Ser104 in epithelial ovarian carcinoma and to explore its clinical significance, and the correlation with the prognosis of epithelial ovarian carcinoma. METHODS: From January 2009 to June 2013, 95 cases of primary ovarian epithelial carcinoma who were admitted to the First Affiliated Hospital of Wannan Medical College Yijishan Hospital for gynecology and obstetrics surgery and pathologically confirmed were selected. All the patients were not treated with chemotherapy before surgery. The expression levels of pPEA-15-Ser104 in 95 cases of primary ovarian epithelial carcinoma were detected by immunohistochemical method.Chi-square test was used to analyze the difference of pPEA-15-Ser104 expression in patients with ovarian cancer with different clinical characteristics. Survival status of patients with ovarian epithelial carcinoma was closely followed up after surgery . Kaplan-Meier (K-M) method was used to analyze the difference of survival rate in patients with ovarian epithelial carcinoma with different clinical characteristics. Multivariate Cox proportional risk regression model was used to analyze prognostic factors in patients with epithelial ovarian carcinoma.RESULTS:There were significant differences in the expression levels of pPEA-15-Ser104 in different histological grades, surgical and pathological stages, types and distant metastasis of ovarian epithelial carcinoma.There was no significant difference in age, tumor location, tumor maximum diameter and lymph node metastasis.K-M survival analysis and Cox regression analysis showed that the prognosis of ovarian cancer patients with high expression of pPEA-15-Ser104 was poor and the survival time was short, which could be used as an independent risk factor for poor prognosis of ovarian cancer (P<0.05).CONCLUSION: Phosphorylated PEA-15 plays an important role in the development of ovarian epithelial carcinoma.The prognosis of the patients with high expression is poor. It may become a new target to predict the prognosis of ovarian cancer patients, and it is expected to provide an important target for the treatment of ovarian cancer patients.

Key words: epithelial ovarian cancer, pPEA-15-Ser104, prognosis, immunohistochemistry

CLC Number:

R965.2
R711

FANG Chuanchuan, NI Guantai, JIN Lan, LIU Ji, LIU Xiaoqing, QIAO Chun, LUO Yonghong. Correlation between phosphorylation of PEA-15-Ser104 site and prognosis of epithelial ovarian cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 523-528.

References

［1］Mcguire V, Jesser CA, Whittemore AS.Survival among U S women with invasive epithelial ovarian cancer［J］. Gynecol Oncol, 2002, 84(3):399-403.
［2］Vigliotta G, Miele C, Santopietro S, et al. Overexpression of the ped/pea-15 Gene causes diabetes by impairing glucose-stimulated insulin secretion in addition to insulin action［J］. Mol Cell Biol, 2004, 24(11):5005-5015.
［3］Geng F, Wu JL, Lu GF, et al.MicroRNA-132 targets PEA-15 and suppresses the progression of astrocytoma in vitro［J］. J Neurooncol, 2016, 129(2):211-220.
［4］吴益峰, 朱柯磊, 陈磊,等.肝细胞性肝癌中磷酸化PED/PEA-15和P-p27T187的表达及临床意义［J］. 现代实用医学, 2016, 28(9):1134-1138.
［5］刘记, 金兰, 罗永红. PED/PEA-15及其磷酸化状态在卵巢上皮肿瘤中的表达及意义［J］.现代妇产科进展, 2016, 25(7):19-22.
［6］陈春林.卵巢肿瘤、输卵管肿瘤及原发性腹膜癌［M］//谢幸，孔北华，段涛，主编. 妇产科学. 9版.北京.人民卫生出版社，2018:313-323.
［7］Harris HR, Babic A, Webb PM, et al. Polycystic ovary syndrome, oligomenorrhea, and risk of ovarian cancer histotypes: Evidence from the Ovarian Cancer Association Consortium［J］. Cancer Epidemiol Biomarkers Prev, 2018, 27(2):174-182.
［8］邓梅君, 刘俊, 李贵玲. 克唑替尼对人卵巢癌细胞系SKOV3细胞增殖的影响［J］. 医药导报, 2017, 36(7):727-730.
［9］Coffman LG, Burgos-Ojeda D, Wu R, et al. New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination［J］.Transl Res，2016, 175:92-102.
［10］Pereria D,Assis J,Gomes M，et al.Improvement of a predictive model in ovarian cancer patiens submitted to platinum-based chemotherapy:implications of a GST activity profile［J］. Eur J Clin Pharmacol，2016，72(5):545-553.
［11］Estellés A, Charlton CA, Blau HM. The phosphoprotein protein PEA-15 inhibits Fas- but increases TNF-R1-mediated caspase-8 activity and apoptosis［J］. Dev Biology, 1999, 216(1):16-28.
［12］Condorelli G , Vigliotta G , Trencia A , et al. Protein kinase C (PKC)-alpha activation inhibits PKC-beta and mediates the action of PED/PEA-15 on glucose transport in the L6 skeletal muscle cells［J］. Diabetes, 2001, 50(6):1244-1252.
［13］Whitehurst AW, Robinson FL, Moore MS, et al. The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions［J］. J Biol Chem, 2004, 279(13):12840-12847.
［14］Bartholomeusz C, Rosen D, Wei C, et al. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival［J］.Cancer Res, 2008, 68(22):9302-9310.
［15］Exler RE , Guo X , Chan D , et al. Biomechanical insult switches pea-15 activity to uncouple its anti-apoptotic function and promote erk mediated tissue remodeling［J］. Exp Cell Res, 2016, 340(2):283-294.
［16］Weng Z , Gao H , Hu J , et al. Isoalantolactone induces autophagic cell death in SKOV3 human ovarian carcinoma cells via upregulation of PEA-15［J］. Oncol Rep, 2016,35(2):833-840.
［17］Formstecher E, Ramos JW, Fauquet M, et al. PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase［J］. Dev Cell, 2001, 1(2):239-250.
［18］Mohammed HN, Pickard MR, Mourtada-Maarabouni M. The protein phosphatase 4- PEA15 axis regulates the survival of breast cancer cells［J］. Cellular Signal, 2016, 28(9):1389-1400.
［19］庄良武, 林岚, 陈捷,等. TRAIL联合顺铂诱导卵巢癌耐药细胞株COC1/DDP凋亡机制的研究［J］. 中国医学创新, 2016, 13(29):17-21.
［20］Krueger J, Chou FL, Glading A, et al. Phosphorylation of phosphoprotein enriched in astrocytes (PEA-15) regulates extracellular signal-regulated kinase-dependent transcription and cell proliferation［J］. Mol Biol Cell, 2005, 16(8):3552-3561.
［21］Florian J，Sulzmaier J ,Mohana K, et al.PEA-15 potentiates H-Ras mediated epithelial cell transformation through Phospholipase D ［J］.Oncogene,2012,26(7): 3547-3560.
［22］Sulzmaier F, Opoku-Ansah J, Ramos JW. Phosphorylation is the switch that turns PEA-15 from tumor suppressor to tumor promoter［J］.Small GTPases,2012, 3(3):173-177.

[1]	SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
[2]	HUANG Kaige, XU Qinhua, WANG Wei. Interaction effect and predictive efficacy of blood glucose and blood calcium on the prognosis of patients with acute severe pancreatitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1227-1234.
[3]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[4]	LIU Le, QI Wenbo, BAI Yuping, LIU Qian, YIN Zhenyu, LI Xiaomei, YU Yang, CHEN Hao. Influencing factors of PD-1/PD-L1 immune checkpoint inhibitor immunotherapy for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 95-101.
[5]	TIAN Yali, FENG Lin, ZHAO Wan, GU Min, SHEN Hanjing, CHAI Xiaoyan. Correlation of BRCA1 gene polymorphism with chemosensitivity and prognosis of metastatic esophageal squamous cell carcinoma treated with cisplatin combined with capecitabine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1118-1126.
[6]	XU Honglei, XU Bingxin, ZU Qing, ZHAO Yan, GAO Pengfei, YU Yang. Effects of CYP2C19 gene polymorphism on the clinical prognosis of clopidogrel in elderly patients with acute cerebral infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1014-1020.
[7]	WANG Xianghai, XING Min, LYU Tangfeng, LIU Hongbing, SONG Yong. Effects of knocking down long intergenic non-coding RNA 00467 on the prognosis of patients with lung adenocarcinoma and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 841-849.
[8]	ZHANG Dezhi, LIU Meng, ZHU Shaogong, LIU Guiju, JI Jie. Efficacy and safety of XELOX therapy in comparison with capecitabine monotherapy in adjuvant chemotherapy for elderly patients with colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 926-936.
[9]	LI Rongzhen, MEI Jiazhuan, XIA Yunzhan, JI Jie. Prognostic factors and safety study of R0 resection colorectal cancer patients received capecitabine based adjuvant chemotherapy in real world [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 704-711.
[10]	BAI Yan, ZHENG Xiaoyong, YANG Yage, FANG Lifeng. Influence of programmed death-ligand 1 genetic variation on the clinical outcomes of postoperative CRC patients received 5-FU based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 180-187.
[11]	LI Wenshu, DONG Huaifu. The value of serum calcitonin in bacterial meningitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1315-1320.
[12]	LI Xiaojie,ZHANG Shengwei,WANG Huasheng,WANG Dong, MEI Jiazhuan, DENG Yewei. Effects of polymorphism of vascular endothelial growth factor A on the prognosis of colorectal cancer patients received fluorouracil based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 900-904.
[13]	SHAN Yan, LI Zhigang. Influence of genetic variation of TNFAIP3 on prognosis among esophageal squamous cell carcinoma patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 820-824.
[14]	CHEN Dong, LU Ying, PEI Renzhi, LOU Yinjun, WANG Jinghan, YE Peipei, ZHANG Pisheng, JIN Jie. Outcome of acute promyelocytic leukemia treated with low dose homoharringtonine, alltrans retinoic acid and arsenic trioxide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 561-569.
[15]	LV Wenlong, CHEN Xiuying, HONG Jinsheng, LIU Feng, ZHANG Weijian. Predictive value of Esophageal tumor volume based on CT measurement for concurrent chemo-radiotherapy with PF program（5-Fu+DDP） [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1373-1379.